Boston Scientific Corp.'s management expects the coronavirus outbreak may cause the company to lose up to $40m in 2020 first-quarter revenues as a result of deferred procedures and disruptions in its supply chains in China.
"Although it is early, the Chinese health care system is highly focused on containing the spread of the virus, and thus, we expect to see a reduction in volume for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?